The present application relates to a free or pharmaceutically acceptable compound, a pharmaceutical compound containing such a compound, and the use of such a compound in the treatment of heterogeneity and progressive fibrosis. Claim 1: a formula compound (1) in free form or acceptable salt form, wherein L is a link (ch832228345)；-CH (CH) --O- (CH₂) ₙ-,-C (O) --C (O) -NH- (CH) -n is 1, 2, 3； R¹ is selected from C₃₋₇ cycloalkyl optionally substituted once or more than once with a substituent independently selected from hydroxyl, halogen, C₁₋₃ alkyl；C₅₋₁₀ bridged cycloalkyl optionally substituted once or more than once with a substituent independently selected from hydroxyl, C₁₋₃ hydroxyalkyl；R2 and R3 are selected independently of H, halogen and c83218c83323 tar；R83088 is a non aromatic heterocycle containing N, which can optionally be composed of one or more extra heteroatoms selected from n or S. in this case, r8311 can be chosen to replace the heterocycle once or more；R⁷ is independently selected from C₁₋₃ alkyl,Hydroxyl oxidation c83217c83183223；Halogenated tar c83218323；C₁₋₃alkoxyC₁₋₃alkyl,haloalkoxy C₁₋₃alkyl C₁₋₃,1. C 83228331 asphalt；C₁₋₃ cyanoalkyl,(CH) -Rm is 0, 1, 2 or 3； R⁸ is selected from a saturated, unsaturated, unsaturated, 4, 5 or 6 membered heterocyclic ring comprising one or more heteroatoms selected from N, O or S, said ring optionally substituted once or more than once with a selected substituent independently of oxo, SO₂-C₁₋₃ alkyl,a. Halogenated tar c83218d318323；or a C₃₋₆ cycloalkyl optionally substituted once or more than once with halo.La presente solicitud se relaciona con un compuesto en forma libre o en forma de sal farmacéuticamente aceptable, a composiciones farmacéuticas que comprenden dicho compuesto y al uso de dicho compuesto en el tratamiento de la osificación heterotópica y fibrodisplasia osificante progresiva. Reivindicación 1: Un compuesto de la fórmula (1) en forma libre ó en forma de sal farmacéuticamente aceptable, en dond
